Zhong Guo Zheng Quan Bao·2025-09-04 18:58Core Viewpoint - Fosun Pharma has transformed from a generic drug company to a high-level innovative enterprise, focusing on innovation and global expansion, reflecting the shift of China's pharmaceutical industry from a follower to a leader in innovation [1] Financial Performance - In the first half of 2025, Fosun Pharma achieved revenue of 19.514 billion yuan and a net profit attributable to shareholders of 1.702 billion yuan, representing a year-on-year growth of 38.96% [1] - Revenue from innovative drugs exceeded 4.3 billion yuan, with a year-on-year increase of 14.26%, driven by product structure optimization and sales growth [1][2] Innovation Strategy - The company has approved 4 innovative drugs and 57 generic drugs during the reporting period, with 4 innovative drugs and 22 generic drugs submitted for market approval [2] - Fosun Pharma aims for a compound annual growth rate of approximately 20% in innovative drug revenue from 2025 to 2027, linking this growth to the increase in net profit attributable to shareholders [2] Global Market Expansion - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for about 28.07% of total revenue, with a focus on building a commercial team in the U.S. for the launch of innovative products [3] - The company has established six regional distribution centers in emerging markets such as Africa and Southeast Asia, providing comprehensive services including drug registration and safety monitoring [3][4] Business Development and Licensing - Fosun Pharma has strengthened its global licensing cooperation, with significant progress in business development for innovative drugs, including the international recognition of its PD-1 monoclonal antibody, Surulitinib [4][5] - The company differentiates between license-in and license-out strategies to enhance its product pipeline and accelerate commercial deployment [5] Strategic Framework - Fosun Pharma adheres to the 4IN strategy: Innovation, Internationalization, Intelligentization, and Integration, aiming to enhance innovation speed and quality, global reach, and embrace AI [6]